Ischemia
Conditions
Brief summary
It is known that several common eye diseases are associated with ocular perfusion abnormalities. Moxaverine is used in the therapy of perfusion abnormalities in the brain, the heart and the extremities because of its direct vasodilatory effects. The present study seeked to investigate whether moxaverine alters ocular blood flow in healthy volunteers after intravenous administration.
Interventions
DRUGMoxaverine
intravenous administration
DRUGphysiological saline
intravenous administration
Sponsors
Medical University of Vienna
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
* 6 healthy volunteers of either sex * Age 18-35 yrs. * Body mass index between 15th and 85th percentile, nonsmokers
Exclusion criteria
* Regular use of medication * Abuse of alcoholic beverages or drugs * Participation in a clinical trial in the 3 weeks preceding the study * Treatment in the previous 3 weeks with any drug * Symptoms of a clinically relevant illness in the 3 weeks before the first study day * History or presence of gastrointestinal, liver or kidney disease, or other conditions known to interfere with distribution, metabolism or excretion of study drugs * Blood donation during the previous 3 weeks * Ametropy less 3 dpt * Acute gastric bleeding, massive cerebral hemorrhage related to stroke * Women: pregnancy or lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Retinal and Choroidal Blood flow | 2 hours |
Countries
Austria
Outcome results
None listed